Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › T-cell lymphoma

T-cell lymphoma

0 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for T-cell lymphoma

10 trials tracked for T-cell lymphoma: 2 in phase 3 or 4 and 1 with published results. The most-cited published study has 730 citations.

10Trials tracked
2Phase 3 & 4
0Recruiting
1With published results
Phase distribution
Phase 4 1 Phase 3 1 Phase 2 6 Phase 1 2
  1. Phase 3 ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas Completed · 730 cited
  2. Phase 4 A Study of Brentuximab Vedotin Treatment in Chinese Adults With CD30-Positive Cutaneous T-Cell Lymphoma Completed
  3. Phase 2 Safety and Efficacy of Tenalisib (RP6530) in Combination With Romidepsin in Patients With Relapsed/Refractory T-cell Lymphoma Completed
  4. Phase 2 Total Body Irradiation +/- Total Lymphoid Irradiation & Anti-Thymocyte Globulin in Non-myeloablative Hematopoietic Cell Transplantation Completed
  5. Phase 2 Efficacy and Safety Study of Fostamatinib Disodium Tablets to Treat T-Cell Lymphoma Completed
  6. Phase 2 A Study for Patients With Non-Hodgkin's Lymphomas Completed
Show 4 more trials
  1. Phase 2 A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL) Completed
  2. Phase 2 Tandem Auto-Allo Transplant for Lymphoma Completed
  3. Phase 1 Palbociclib in Combination With Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL) Completed
  4. Phase 1 A Pilot Study of Sorafenib Examining Biomarkers in Refractory or Relapsed T-Cell Lymphoma Patients Completed

Showing the 10 most-cited and recently-updated of 10 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found For clinicians

T-cell lymphoma: what the trials found

Brentuximab vedotin has demonstrated clinical activity in patients with CD30+ MF or pcALCL, achieving an Overall Response Rate (ORR) of 60.0% for responses lasting at least 4 months 1.

Evidence supporting the use of Brentuximab vedotin is established across multiple study phases, including Phase 2 and Phase 3 trials [2, 3].

Recent results — preliminary, needs further review

  • Tenalisib was evaluated in a Phase 2 trial (N=33) but results are not yet corroborated 4.
  • Anti-thymocyte globulin (ATG) was investigated in a Phase 2 trial (N=22) with unconfirmed findings 5.
  • Enzastaurin showed a tumor response rate of 0% in a Phase 2 study, with varying progression-free survival at 1-year among participants 6.
  • Busulfan conditioning for allogeneic transplant resulted in an average of 12 days to reach an absolute neutrophil count of $\ge$500/uL 7.
  • Fostamatinib Disodium, Palbociclib, and Sorafenib were evaluated in Phase 1 or Phase 2 trials, but results are not yet corroborated [8, 9, 10].

For the clinician treating this condition

  • Brentuximab vedotin is an established option for CD30+ MF or pcALCL with a reported ORR of 60.0% for responses lasting at least 4 months.
  • Multiple clinical trials have evaluated Brentuximab vedotin across various phases, supporting its role in the treatment landscape.

AI synthesis of 5 cited trials, updated Aug 12, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
No published articles yet for this condition. Check back soon.